cdc7 in 1

Cdc7-IN-1 is a highly selective and ATP competitive inhibitor of Cdc7 kinase (IC50: 0.6 nM at 1 mM ATP). It potently inhibits Cdc7 activity in cancer cells and effectively induces cell death.

Cdc7-IN-15 (Example 108) is a cdc7 kinase inhibitor with potential applications in cancer research [1].

Cdc7-IN-17 is a potent inhibitor of CDC7 with an IC50 of <10 μM, applicable in cancer research [1].

Cdc7-IN-12 (compound 1) is a potent CDC7 inhibitor (IC50 < 1 nM) with potential applications in cancer research, demonstrating antiproliferative activity in COLO205 cells with an IC50 of 100-1000 nM [1].

LY3143921 ((S)-Example 2) is an orally active inhibitor of CDC7 kinase with broad in vitro anticancer activity [1].

Cdc7-IN-9 can be used for the research of cancer which is a potent inhibitor of Cdc7 [1].

Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC50 of 1.49 nM [1].

Cdc7-IN-8, a potent inhibitor, targets Cdc7, a serine threonine kinase responsible for activating MCM promotion through phosphorylation of the microchromosome maintenance protein (MCM protein). MCM protein, an essential component of DNA replication initiation, plays a crucial role. Cdc7-IN-8 holds promise in cancer disease research (WO2021032170A1, compound 1-1 1-2) [1].

Cdc7-IN-13 (compound 84) is a highly potent CDC7 inhibitor with an IC50 value of less than 1 nM, showing significant potential for cancer research [1].

Cdc7-IN-14 (compound 82) is a highly potent CDC7 inhibitor with an IC50 value of less than 1 nM, exhibiting promising potential for cancer research [1].

(S)-Cdc7-IN-18, a potent CDC7 inhibitor, effectively impedes the overactivation of MCM2, a crucial tumor cell marker, induced by huCdc7 overexpression. Consequently, it inhibits the aberrant proliferation of tumor cells. This compound, exhibits promise for cancer disease research [1].

Cdc7-IN-18 (compound 1-2) is a highly effective inhibitor of the CDC7 enzyme, with an IC50 value of 1.29 nM for the Cdc7 DBF4 enzyme. Additionally, this compound exhibits strong antiproliferative activities, with an IC50 value of 53.62 nM in COLO205 cells [1].

Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.

Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.

LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].